Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of January 2026, with a specific reporting date of January 23, 2026. Enlivex Therapeutics Ltd., an Israeli company, filed this report to disclose a significant corporate action regarding its listing status.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
On January 23, 2026, the Company announced the initiation of a process to voluntarily delist its ordinary shares (par value NIS 0.40 per share) from trading on the Tel Aviv Stock Exchange (TASE). This represents a material change in the Company's capital market presence.
Outlook, Risks, and Management Commentary
Management, represented by CEO Oren Hershkovitz, has formally initiated the delisting process. The filing incorporates a press release (Exhibit 99.1) detailing this decision. The text does not provide specific guidance on future operations, detailed risk factors, or contingencies beyond the delisting action itself.
Investor Verification Checklist
- Verify the status and timeline of the voluntary delisting from the Tel Aviv Stock Exchange.
- Confirm the continued trading status of shares on other exchanges, if applicable.
- Review the full text of the press release (Exhibit 99.1) for specific reasons behind the delisting decision.
- Check for any subsequent filings regarding the completion of the delisting process.